Shares of STAAR Surgical surged 11.4% in after-hours trading to $30.26 after the maker of implantable lenses for vision correction posted third-quarter results that cleared a low bar — raising a pointed question about whether the stock's bounce reflects genuine momentum or merely the fading of a one-time accounting headwind. STAAR Surgical Clears Its China Hurdle and Pops 11%, but Is the Ugly Headline Number Hiding Real Progress or Real Problems?

Shares of STAAR Surgical jumped 11.4% to $30.26 in after-hours trading after the implantable-lens maker posted third-quarter results that handily beat Wall Street forecasts on both revenue and earnings. The beat came despite a headline sales decline that, on the surface, looks alarming — forcing investors to decide whether the company's underlying growth justifies a stock that has rallied more than 23% in a week.

• The Numbers Beat by a Wide Margin, but the Bar Was Low

Revenue of $83.4 million topped analysts' consensus of $78.2 million — a 6.7% beat — while GAAP earnings of $0.11 per share more than doubled the $0.05 estimate.

Adjusted earnings of $0.34 also topped the Zacks average of $0.19. The beats look impressive in percentage terms, but they were measured against expectations that had already been slashed to reflect a known one-time comparison problem in China.

• Strip Out Last Year's China Catch-Up and Sales Actually Grew 21%

Reported sales fell 12% year over year, but that drop is almost entirely explained by $25.9 million in deferred China revenue that was booked in Q3 2025, creating a 33-percentage-point headwind. Excluding that item, sales rose 21%.

China sales of $39.3 million were up 31% on the same adjusted basis, while EMEA surged 31% and U.S. sales hit $6.5 million — the third straight quarter above $6 million. The geographic breadth matters: STAAR's long-standing dependence on China is slowly moderating.

• Margins Compressed, but Management Says Relief Is Coming

Gross margin fell to 70.9% from 82.2% a year ago, pressured by the deferred-revenue comparison and higher manufacturing costs.

The company is shifting all China-bound production to its Swiss factory to dodge tariffs, a move targeted for completion by year-end that should lift margins afterward.

• A Clean Balance Sheet Buys Time

Cash and investments totaled $206.4 million — up $24.9 million from the prior quarter — with no debt.

Stifel recently upgraded the stock to Buy with a $31 price target, arguing STAAR can compound revenue at 11% annually through 2028 versus the Street's 8% estimate. At the current price, the stock is already testing that target — leaving little room for disappointment if the China recovery stumbles or margins don't improve as promised.